Kymera Therapeutics Inc. (KYMR)
$118.63
$-0.42
(-0.35%)
As on 02-Sep-2026 16:00EDT
Market cap
$9,719 Mln
Revenue (TTM)
$105 Mln
P/E Ratio
--
P/B Ratio
6.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-9.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.3
-
Face value
--
-
Shares outstanding
82,257,588
6 Years Aggregate
CFO
$-296.69 Mln
EBITDA
$-504.97 Mln
Net Profit
$-503.49 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kymera Therapeutics (KYMR)
| 52.5 | 14.7 | 51.2 | 187.9 | 81.4 | 14.2 | -- |
|
BSE Sensex*
| -9.2 | -1.5 | 3.0 | -4.1 | 5.6 | 5.9 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Kymera Therapeutics (KYMR)
| 93.4 | 57.4 | 2.0 | -60.7 | 2.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kymera Therapeutics (KYMR)
|
118.6 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 |
| 85.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 369.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 546.9 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 357.5 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.1 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Kymera Therapeutics (KYMR)
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation... system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Read more
-
Co-Founder & Chairman
Dr. Bruce L. Booth DPHIL, Ph.D.
-
Co-Founder & Chairman
Dr. Bruce L. Booth DPHIL, Ph.D.
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kymera Therapeutics (KYMR)
What is the current share price of Kymera Therapeutics Inc (KYMR) Today?
The share price of Kymera Therapeutics Inc (KYMR) is $118.63 (NASDAQ) as of 02-Sep-2026 16:00 EDT. Kymera Therapeutics Inc (KYMR) has given a return of 81.44% in the last 3 years.
What is the current PB & PE ratio of Kymera Therapeutics Inc (KYMR)?
Since, TTM earnings of Kymera Therapeutics Inc (KYMR) is negative, P/E ratio is not available.
The P/B ratio of Kymera Therapeutics Inc (KYMR) is 6.61 times as on 28-Aug-2026, a 28 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-21.09 |
4.16 |
2024 |
-14.37 |
3.85 |
2023 |
-10.14 |
3.77 |
2022 |
-9.33 |
2.95 |
2021 |
-32.56 |
7.10 |
What is the 52 Week High and Low of Kymera Therapeutics Inc (KYMR)?
The 52-week high and low of Kymera Therapeutics Inc (KYMR) are Rs 130.05 and Rs 39.84 as of 03-Sep-2026.
What is the market cap of Kymera Therapeutics Inc (KYMR)?
Kymera Therapeutics Inc (KYMR) has a market capitalisation of $ 9,719 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kymera Therapeutics Inc (KYMR)?
Before investing in Kymera Therapeutics Inc (KYMR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.